Neurology
-
Randomized Controlled Trial
Phase II/III randomized trial of TCH346 in patients with ALS.
TCH346 exerts antiapoptotic effects by binding to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and blocking the apoptotic pathway in which GAPDH is involved. Apoptosis is considered to be a key pathogenic mechanism in neurodegenerative diseases including ALS. ⋯ The trial revealed no evidence of a beneficial effect of TCH346 on disease progression in patients with ALS.